Literature DB >> 30151658

Candida parapsilosis Vaginal Infection-a New Site of Azole Drug Resistance.

J D Sobel1, S Suprapaneni2.   

Abstract

PURPOSE OF REVIEW: Evaluation of pathogenicity of an uncommon vaginal Candida species, Candida parapsilosis with particular references to susceptibility to conventional antifungal agents. RECENT
FINDINGS: C. parapsilosis vaginal isolates usually present in asymptomatic women as commensals but may induce vulvovaginal symptoms indistinguishable from C. albicans requiring antifungal therapy; however, recent experience reveals clinically relevant resistance to the azole class of antimycotics.
CONCLUSION: Clinicians are required to determine a causal relationship between vaginal isolates of C. parapsilosis before prescribing antifungal agents, recognizing the possibility of fluconazole resistance to explain refractory symptomatology.

Entities:  

Keywords:  Candida parapsilosis; Commensal; Fluconazole resistance; Pathogen; Vaginitis

Year:  2018        PMID: 30151658     DOI: 10.1007/s11908-018-0649-2

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  30 in total

1.  Emergence of non-albicans Candida among candidal vulvovaginitis cases and study of their potential virulence factors, from a tertiary care center, North India.

Authors:  Varsha Kumari; Tuhina Banerjee; Pankaj Kumar; Sulekha Pandey; Ragini Tilak
Journal:  Indian J Pathol Microbiol       Date:  2013 Apr-Jun       Impact factor: 0.740

2.  In vitro susceptibility profile of 200 recent clinical isolates of Candida spp. to topical antifungal treatments of vulvovaginal candidiasis, the imidazoles and nystatin agents.

Authors:  F Choukri; M Benderdouche; P Sednaoui
Journal:  J Mycol Med       Date:  2014-10-23       Impact factor: 2.391

3.  Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III.

Authors:  Arianna Tavanti; Amanda D Davidson; Neil A R Gow; Martin C J Maiden; Frank C Odds
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

4.  Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases.

Authors:  Sandra S Richter; Rudolph P Galask; Shawn A Messer; Richard J Hollis; Daniel J Diekema; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

5.  Prevalence & susceptibility to fluconazole of Candida species causing vulvovaginitis.

Authors:  Srujana Mohanty; Immaculata Xess; Fahmi Hasan; Arti Kapil; Suneeta Mittal; Jorge E Tolosa
Journal:  Indian J Med Res       Date:  2007-09       Impact factor: 2.375

6.  Clinical characteristics of vulvovaginal candidiasis and antifungal susceptibilities of Candida species isolates among patients in southern China from 2003 to 2006.

Authors:  Shang Rong Fan; Xiao Ping Liu; Jian Wu Li
Journal:  J Obstet Gynaecol Res       Date:  2008-08       Impact factor: 1.730

7.  Three distinct genotypes within Candida parapsilosis from clinical sources.

Authors:  D Lin; L C Wu; M G Rinaldi; P F Lehmann
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

8.  Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates.

Authors:  M E Lynch; J D Sobel
Journal:  J Med Vet Mycol       Date:  1994

9.  Vaginopathic and proteolytic Candida species in outpatients attending a gynaecology clinic.

Authors:  L Agatensi; F Franchi; F Mondello; R L Bevilacqua; T Ceddia; F De Bernardis; A Cassone
Journal:  J Clin Pathol       Date:  1991-10       Impact factor: 3.411

10.  Differentiation between women with vulvovaginal symptoms who are positive or negative for Candida species by culture.

Authors:  L M Linhares; S S Witkin; S D Miranda; A M Fonseca; J A Pinotti; W J Ledger
Journal:  Infect Dis Obstet Gynecol       Date:  2001
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.